Tevogen Bio is advancing its investigational T cell therapy, TVGN 489, which shows promise as a potential treatment for Long COVID by targeting persistent viral reservoirs linked to the condition.

Dr. Ryan Saadi, CEO of Tevogen, expressed optimism about TVGN 489's ability to restore immune balance in Long COVID patients and noted that the company is preparing for clinical manufacturing to support its development.

This therapy aims to provide broad, durable immune responses, representing a significant step forward in addressing the large unmet medical need among the approximately 20 million Americans affected by Long COVID.

Recent peer-reviewed studies published in prominent medical journals have documented the persistence of SARS-CoV-2 proteins and RNA in individuals months to years after initial infection, suggesting the presence of viral reservoirs that may drive Long COVID symptoms.

These residual viral components contribute to chronic immune inflammation, which is believed to be a key factor in Long COVID, highlighting the importance of therapies like TVGN 489 that target infected cells.

In clinical trials, TVGN 489, an off-the-shelf cytotoxic CD8+ T cell therapy targeting multiple SARS-CoV-2 proteins, successfully reduced viral load in all patients and demonstrated T cell persistence for at least six months.

Designed to target multiple viral proteins across the SARS-CoV-2 genome, TVGN 489 aims to eliminate infected cells and induce a broad, durable immune response without interfering with patients' existing immune functions.

Given the significant unmet medical need and the large population affected, TVGN 489 could substantially impact the treatment landscape for Long COVID, offering hope for a condition with limited current options.

Tevogen's research and development efforts include forward-looking statements about market strategies and potential risks such as funding, regulatory approval, competition, and technological challenges, which are typical hurdles for biotech innovation.